Corporate News
Neukio Biotherapeutics and Tofflon Life Sciences Successfully Deliver Customized Glass Bioreactors
2024-07-19
China (Shanghai) Pilot Free Trade Zone June 24, 2024 - Neukio Bio, a biotech company dedicated to developing scalable iPSC-CAR-NK based allogeneic and homogenic cell therapies for solid tumor indications and autoimmune diseases, held a ceremony with Tofflon Life Sciences for the delivery of the first batch of custom-made glass bioreactors. This delivery results from previous collaborative efforts between staff from the two companies in developing a fit-for-purpose manufacturing process for iPSC derived NK product, It also marks an important stage of their collaboration to validate and adopt the customer-made bioreactors in routine scale-up manufacturing. and signifies a new chapter for the in-depth cooperation in the CGT field. Going forward, by leveraging both respective strengths, we will further integrate 3D intelligent automation equipment into the standardization of allogenic cell manufacturing, contributing to the industry and helping patients.
During the event, Neukio Bio's Chairman, Dr. Richard Wang, along with VP of CMC Dr. Hongliang Zong, VP of Business Development and Strategy Dr. Mu Sun, and Tofflon Life Sciences' General Manager of the Life Science, Mr. Jinsheng Cheng, and Deputy General Manager Mr. Liang Nie, engaged in an in-depth discussions with core technical members from both companies to explore further collaboration areas addressing the challenges gene therapy (CGT) industry facing, and solutions they can work out together.
Chairman Richard Wang of Neukio Bio said:
" Neukio is dedicated to developing universal, off-the-shelf, scalable immune cell therapy for solid tumors indications and autoimmune diseases, based on innovative iPSC-CAR-NK-based approach,. Our proprietary platform and pipeline are designed for scalable manufacturing and have been optimized for efficiency and economy. We've independently pioneered a closed-system, suspension culture with perfusionand feeder-free culturing, fill/finish, and cryopreservation process, making it the most advanced iPSC-CAR-NK process that can manufacture in large scale so far. However, as no such products have been approved for marketing worldwide, Neukio seeks to collaborate with experienced industrial partners, like Tofflon, for development and validation of automated equipment, including bioreactors, for commercial manufacturing. This collaboration is crucial for bringing our innovative therapies to the market."
